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Supplemental Experimental Procedures

Antibodies and reagents
The following antibodies were used in our studies: anti-Dock180 (H-4 and N-19 The puromycin-resistant cell populations were expanded and examined for efficiency of Src knockdown by IB analysis.
Plasmids
The pcDNA3-Flag-Dock180 plasmid was derived from a pCXN2-Flag-Dock180 (a gift from Dr. M. Matsuda) (6) . Briefly, a 596-bp DNA fragment of pCXN2-Dock180 amplified by PCR was cloned into a pcDNA3 vector (Invitrogen) with XhoI and XbaI to generate a pcDNA3-Flag-Dock180-XbaI. Then a 5.314-kb DNA fragment released from a pCXN2-Dock180 by
XbaI was ligated to a pcDNA3-Flag-Dock180-XbaI to generate a pcDNA3-Flag-Dock180.
The pcDNA3-(His) 6 -Dock180 plasmid was derived from a pcDNA3-Flag-Dock180.
pcDNA3-PDGFRα ∆8,9 was derived from a pUC119-PDGFRα ∆8,9 (a gift from Dr. I. Clarke) (7). pLVX-Flag-Dock180 plasmid was constructed from a pcDNA3-Flag-Dock180
(Clontech). pMXI-PDGFRα and pMXI-PDGFA were generated from a pcDNA3-PDGFRα and a pLNCX2-PDGFA (a gift from Dr. C.-H. Heldin), respectively. pEBB-CrkII wild type, pSGT-Src-wild type, Src-kinase dead and Src-Y527F were the gifts from Drs. R. Birge and S. Courtneidge, respectively. A pcDNA3-EGFP-Rac1-WT (Addgene plasmid 12980) was purchased from Addgene Inc. (Cambridge, MA) (8).
Deletion Mutants and Mutagenesis
To construct pcDNA3-Flag-Dock180-∆DHR1 or -∆DHR2, the fragment including -∆DHR1
or -∆DHR2 released from pcDNA3.1-Dock180-∆DHR1 or -∆DHR2 by XbaI was cloned to a pcDNA3-Flag-Dock180-XbaI (9). pcDNA3-Flag-Dock180-ApaI, -∆DHR1-ApaI, -∆DHR1-ApaI-StuI, -∆DHR1-ApaI-PvuI, and -∆DHR1-ApaI-BglII was derived from pcDNA3-Flag- Mutant constructs were verified by automated DNA sequencing.
Cell Proliferation and Viability Assays
In vitro cell proliferation analyses of various glioma cell lines were performed as we recently described (10) . Briefly, 50,000 cells were seeded in 10% FBS/ DMEM, split, counted, and re-seeded every 2 days in a 6-well plate. Population doubling was calculated by dividing the total cell number by the cells seeded (50,000 cells), using log2 versus the days in culture to determine the proliferation rate of each type of cells.
To determine cell survival and apoptosis, various cells were plated on 8-well chamber slides. After overnight incubation, the medium was replaced with fresh DMEM plus 0.5% FBS. After 48 hr, slides were fixed by 4% formaldehyde in ice-cold PBS and permeabilized with 0.2% Triton X-100 solution. After equilibration, slides were immersed in TUNEL reaction buffer at 37°C for 60 min inside the humidified chamber. Reaction was stopped by 2X saline sodium citrate (SSC) and slides were counterstained with Hoechst 33258 and mounted in VECTASHIELD (Vector Lab). One thousand cells of each slide were randomly examined and numbers of TUNEL-positive cells were counted under a microscope equipped with a SPOT digital camera. The data were analyzed using GraphPad Software.
In vitro Cell Migration and Rac1 Activation Assays
In vitro cell migration assays were performed as we previously described (5). Briefly, various cells were serum-starved for 24 hr, washed with PBS and resuspended in DMEM plus 0.1% FBS. 50 µl of cells (5 x 10 5 /ml) was placed into the top compartment of a Boyden chamber and the bottom chamber was added with or without 50 ng/ml PDGF-A and indicated inhibitors. The cells were allowed to migrate through an 8-µm pore size membrane precoated with fibronectin (10 µg/ml) for 10 or 16 hr at 37°C. Afterwards, the membrane was fixed, stained and analyzed. Rac1 activation assays were preformed using a Rac1 activation assay kit (Millipore-Upstate) as we previously described (4).
Gene expression analysis
Total RNA extracted from glioma cell lines was used as template for the generation of The gene expression data for 54 GBM tumor samples classified into proneural group (3) were downloaded from the TCGA data portal; expression values of these 14 genes in these samples were extracted. Expression profile of above signature genes in a sample was also represented as a 14-dimensional unit vector. The similarity of two gene expression profiles was measured using a linear algebra metric referred to as "dot product" . Values ≥5 were considered as gene amplification and values between 2 and 5 were considered as increased gene copy numbers (1, 2).
Immunoprecipitation (IP) and Immunoblotting (IB)
that were treated with or without 50 ng/ml PDGF-A or indicated inhibitors were lysed in an IP buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 2 mM Na 3 VO 4 , 5 mM NaF, 1%Triton X-100 and protease inhibitor cocktail ) at 4°C for 30 min. The lysates were centrifuged for 20 min at 12,000 x g to remove debris. Protein concentrations were determined with a BCA protein assay kit. Equal amounts of cell lysates were immunoprecipitated with specific antibodies and protein G-agarose beads (Invitrogen).
Immunoprecipitates were washed five times with IP buffer, resolved in a 2X SDS lysis buffer and analyzed by IB (5, 10).
Mouse glioma xenografts
All animal experiments were approved by Institutional Animal Care and Use Committee removed, processed, and analyzed as previously described (10) .
